Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
205.00
+16.33 (8.66%)
At close: Oct 5, 2026, 4:00 PM EDT
210.00
+5.00 (2.44%)
Pre-market: Oct 6, 2026, 9:28 AM EDT
Twist Bioscience Revenue
Twist Bioscience had revenue of $118.38M in the quarter ending June 30, 2026, with 23.24% growth. This brings the company's revenue in the last twelve months to $431.80M, up 19.19% year-over-year. In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth.
Revenue (ttm)
$431.80M
Revenue Growth
+19.19%
P/S Ratio
29.77
Revenue / Employee
$441,060
Employees
979
Market Cap
12.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 776.57M |
| BridgeBio Pharma | 713.07M |
TWST News
- 5 days ago - Twist Bioscience price target raised to $212 from $107 at Guggenheim - TheFly
- 6 days ago - The Top HealthTech Questions Landing on Our Desks - ETF Trends
- 7 days ago - Twist Bioscience price target raised to $190 from $160 at Leerink - TheFly
- 11 days ago - Twist Bioscience rises 6.9% - TheFly
- 19 days ago - Twist Bioscience price target raised to $160 from $120 at Leerink - TheFly
- 20 days ago - Twist Bioscience enters agreement with Lilly TuneLab - TheFly
- 20 days ago - Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery - Business Wire
- 20 days ago - Twist Bioscience says Anthropic pilot work factored in FY27 orders expectations - TheFly